Scarica l'app Stockscreener
25.17
8.04%
-2.20
Dopo l'orario di chiusura:
25.15
-0.02
-0.08%
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
4 High-Risk Stocks Built for Big Returns - The Motley Fool
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Total equity of Viking Therapeutics, Inc. – HAN:1VT - TradingView
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - Yahoo Finance
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Viking Therapeutics Inc (Derivatives) to Chinese Yuan Price Today | Live VKTX to CNY Converter & Exchange Rate - CryptoRank
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know - Zacks Investment Research
Viking Therapeutics Inc (Derivatives) - CryptoRank
Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months - Yahoo Finance
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
VKTX Advances Obesity Program With New Oral Maintenance Study - Zacks Investment Research
Viking Therapeutics starts oral trial as Truist targets Viking Therapeutics stock at USD 87 - AD HOC NEWS
Viking Therapeutics Starts VK2735 Obesity Maintenance Trial - grafa.com
VKTX Down 16% in a Month: Time to Invest or Exit the Stock? - Yahoo Finance
VKTX Down 16% in a Month: Time to Invest or Exit the Stock? - TradingView
Viking Therapeutics begins oral VK2735 maintenance trial in obesity - Mugglehead Investment Magazine
Viking Therapeutics initiates oral maintenance dosing study - Investing.com
Viking Therapeutics Inc (Derivatives) price today, VKTX to USD live price, marketcap and chart - CoinMarketCap
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity - PR Newswire
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity - Yahoo Finance
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock - The Motley Fool
Here Are My Top 4 Stocks to Buy in October - The Motley Fool
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits
VKTXObesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis - Simply Wall Street
Viking Therapeutics Inc (MIL:1VKTX) Stock Price, Trades & News - GuruFocus
Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy? - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) - Yahoo! Finance Canada
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price? - Yahoo Finance
Prediction: This Stock Could Double Over the Next 5 Years - The Motley Fool
Inventory turnover of Viking Therapeutics, Inc. – HAN:1VT - TradingView
Viking Therapeutics Slides as Financing Overhang Appears to Weigh on Shares - Quiver Quantitative
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors - Zacks Investment Research
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - The Motley Fool
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - sg.finance.yahoo.com
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - Yahoo Finance
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks - Yahoo Finance
Viking Therapeutics (VKTX) Raises $575M in Upsized Stock and Con - GuruFocus
Viking Therapeutics Raises Capital via Equity and Convertibles - TipRanks
4.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):